HR 872 · 105th Congress · Commerce

Biomaterials Access Assurance Act of 1998

Introduced 1997-02-27· Sponsored by Rep. Gekas, George W. [R-PA-17]· House

Bill Progress

1
Introduced
Committee
House Vote
Senate
Enacted
Latest: Became Public Law No: 105-230.(1998-08-13)

Plain Language Summary

[AI summary unavailable — showing source text] Biomaterials Access Assurance Act of 1997 - Provides that, in any civil action, a biomaterials supplier (one who supplies components or raw materials used to manufacture implants) may raise any defense provided under this Act. Exempts a biomaterials supplier from liability for harm to a claimant caused by an implant, with exceptions in the case of a supplier who: (1) is a registered manufacturer of the implant; (2) is a seller of the implant and who held title to the implant at the time of sale (or is related by common ownership or control to such a seller); or (3) furnishes raw materials or components that fail to meet applicable contractual requirements or specifications. States that a supplier may be considered a manufacturer of an implant, for purposes of such civil actions, only if the supplier has registered with the Secretary of Health and Human Services and included the implant on a list of devices filed pursuant to the Federal Food, Drug, and Cosmetic Act. Requires claimant payment of attorney's fees if the court finds the claim to be without merit and frivolous.…

Summarized by Claude AI · Non-partisan · For informational purposes only

CBO Cost Estimate

Congressional Budget Office

H.R. 872, Biomaterials Access Assurance Act of 1998

Apr 13, 1998

Cost estimate for the bill as ordered reported by the House Committee on the Judiciary on April 1, 1998

Full CBO report ↗

H.R. 872, Biomaterials Access Assurance Act of 1998

Jun 30, 1998

Cost estimate for the bill as ordered reported by the House Committee on Commerce on June 24, 1998

Full CBO report ↗

Official non-partisan budget analysis by the Congressional Budget Office

Cosponsors (20)

4 Democrats16 Republicans